518 related articles for article (PubMed ID: 31035599)
21. Fragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon.
Hagerman RJ; Hagerman PJ
Annu Rev Pharmacol Toxicol; 2022 Jan; 62():365-381. PubMed ID: 34499526
[TBL] [Abstract][Full Text] [Related]
22. Fragile X-like behaviors and abnormal cortical dendritic spines in cytoplasmic FMR1-interacting protein 2-mutant mice.
Han K; Chen H; Gennarino VA; Richman R; Lu HC; Zoghbi HY
Hum Mol Genet; 2015 Apr; 24(7):1813-23. PubMed ID: 25432536
[TBL] [Abstract][Full Text] [Related]
23. Translational endpoints in fragile X syndrome.
de Esch CE; Zeidler S; Willemsen R
Neurosci Biobehav Rev; 2014 Oct; 46 Pt 2():256-69. PubMed ID: 24184744
[TBL] [Abstract][Full Text] [Related]
24. Fragile X syndrome: A review of clinical management.
Lozano R; Azarang A; Wilaisakditipakorn T; Hagerman RJ
Intractable Rare Dis Res; 2016 Aug; 5(3):145-57. PubMed ID: 27672537
[TBL] [Abstract][Full Text] [Related]
25. Fmr1 deficiency promotes age-dependent alterations in the cortical synaptic proteome.
Tang B; Wang T; Wan H; Han L; Qin X; Zhang Y; Wang J; Yu C; Berton F; Francesconi W; Yates JR; Vanderklish PW; Liao L
Proc Natl Acad Sci U S A; 2015 Aug; 112(34):E4697-706. PubMed ID: 26307763
[TBL] [Abstract][Full Text] [Related]
26. BDNF in fragile X syndrome.
Castrén ML; Castrén E
Neuropharmacology; 2014 Jan; 76 Pt C():729-36. PubMed ID: 23727436
[TBL] [Abstract][Full Text] [Related]
27. Transcriptional Reactivation of the FMR1 Gene. A Possible Approach to the Treatment of the Fragile X Syndrome.
Tabolacci E; Palumbo F; Nobile V; Neri G
Genes (Basel); 2016 Aug; 7(8):. PubMed ID: 27548224
[TBL] [Abstract][Full Text] [Related]
28. Hippocampal dysfunction and cognitive impairment in Fragile-X Syndrome.
Bostrom C; Yau SY; Majaess N; Vetrici M; Gil-Mohapel J; Christie BR
Neurosci Biobehav Rev; 2016 Sep; 68():563-574. PubMed ID: 27345143
[TBL] [Abstract][Full Text] [Related]
29. Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome.
Lovelace JW; Wen TH; Reinhard S; Hsu MS; Sidhu H; Ethell IM; Binder DK; Razak KA
Neurobiol Dis; 2016 May; 89():126-35. PubMed ID: 26850918
[TBL] [Abstract][Full Text] [Related]
30. Modelling fragile X syndrome in the laboratory setting: A behavioral perspective.
Melancia F; Trezza V
Behav Brain Res; 2018 Sep; 350():149-163. PubMed ID: 29704597
[TBL] [Abstract][Full Text] [Related]
31. Molecular and cellular aspects of mental retardation in the Fragile X syndrome: from gene mutation/s to spine dysmorphogenesis.
De Rubeis S; Fernández E; Buzzi A; Di Marino D; Bagni C
Adv Exp Med Biol; 2012; 970():517-51. PubMed ID: 22351071
[TBL] [Abstract][Full Text] [Related]
32. Targeted Reactivation of
Haenfler JM; Skariah G; Rodriguez CM; Monteiro da Rocha A; Parent JM; Smith GD; Todd PK
Front Mol Neurosci; 2018; 11():282. PubMed ID: 30158855
[TBL] [Abstract][Full Text] [Related]
33. Disruption of GpI mGluR-Dependent Cav2.3 Translation in a Mouse Model of Fragile X Syndrome.
Gray EE; Murphy JG; Liu Y; Trang I; Tabor GT; Lin L; Hoffman DA
J Neurosci; 2019 Sep; 39(38):7453-7464. PubMed ID: 31350260
[TBL] [Abstract][Full Text] [Related]
34. Incomplete silencing of full mutation alleles in males with fragile X syndrome is associated with autistic features.
Baker EK; Arpone M; Aliaga SM; Bretherton L; Kraan CM; Bui M; Slater HR; Ling L; Francis D; Hunter MF; Elliott J; Rogers C; Field M; Cohen J; Cornish K; Santa Maria L; Faundes V; Curotto B; Morales P; Trigo C; Salas I; Alliende AM; Amor DJ; Godler DE
Mol Autism; 2019; 10():21. PubMed ID: 31073396
[TBL] [Abstract][Full Text] [Related]
35. Variable Expressivity in Fragile X Syndrome: Towards the Identification of Molecular Characteristics That Modify the Phenotype.
Payán-Gómez C; Ramirez-Cheyne J; Saldarriaga W
Appl Clin Genet; 2021; 14():305-312. PubMed ID: 34262328
[TBL] [Abstract][Full Text] [Related]
36. Fragile X Mental Retardation Protein and Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome: A Pilot Study.
Brašić JR; Goodman JA; Nandi A; Russell DS; Jennings D; Barret O; Martin SD; Slifer K; Sedlak T; Mathur AK; Seibyl JP; Berry-Kravis EM; Wong DF; Budimirovic DB
Brain Sci; 2022 Feb; 12(3):. PubMed ID: 35326270
[TBL] [Abstract][Full Text] [Related]
37. Human pluripotent stem cell models of Fragile X syndrome.
Bhattacharyya A; Zhao X
Mol Cell Neurosci; 2016 Jun; 73():43-51. PubMed ID: 26640241
[TBL] [Abstract][Full Text] [Related]
38. Changes in insulin-like growth factor signaling alter phenotypes in Fragile X Mice.
Wise TL
Genes Brain Behav; 2017 Feb; 16(2):241-249. PubMed ID: 27643697
[TBL] [Abstract][Full Text] [Related]
39. Neurological, Psychiatric, and Multisystemic Involvement of Fragile X Syndrome Along With Its Pathophysiology, Methods of Screening, and Current Treatment Modalities.
Ranjan R; Jha S; Prajjwal P; Chaudhary A; Dudeja P; Vora N; Mateen MA; Yousuf MA; Chaudhary B
Cureus; 2023 Feb; 15(2):e35505. PubMed ID: 37007359
[TBL] [Abstract][Full Text] [Related]
40. High-Throughput Screening to Identify Compounds That Increase Fragile X Mental Retardation Protein Expression in Neural Stem Cells Differentiated From Fragile X Syndrome Patient-Derived Induced Pluripotent Stem Cells.
Kumari D; Swaroop M; Southall N; Huang W; Zheng W; Usdin K
Stem Cells Transl Med; 2015 Jul; 4(7):800-8. PubMed ID: 25999519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
